Novavax to Expand Facility for COVID-19 Vaccine Manufacture
Novavax has announced plans to expand its Gaithersburg, Md., facility to support the development and manufacturing of its COVID-19 and influenza vaccines.
The drugmaker’s vaccine candidate, NVX-CoV2373, is currently being evaluated in late-stage global studies with additional trials scheduled to begin in the U.S. and Mexico this month.
Tiny in comparison with its competitors in the race for an approved COVID-19 vaccine, the company is not short of funding, having received an estimated $1.6 billion from the U.S. government’s Operation Warp Speed and $388 million from the Coalition for Epidemic Preparedness Innovations for vaccine-related research and development.
In addition to NVX-CoV2373, the company is also eyeing a combined influenza/COVID-19 vaccine for post-pandemic use.